SEVERE INSULIN RESISTANCE REQUIRING HIGH DOSE INSULIN IMPROVED WITH ADD-ON EMPAGLIFOZIN THERAPY

A CASE REPORT

Authors

  • Xin Yi Ooi Hospital Sultan Haji Ahmad Shah, Temerloh, Malaysia
  • Chee Keong See Hospital Sultan Haji Ahmad Shah, Temerloh, Malaysia
  • Noorhidayah Arifin Hospital Sultan Haji Ahmad Shah, Temerloh, Malaysia

Keywords:

insulin resistance, obesity, empaglifozin

Abstract

INTRODUCTION
Empagliflozin, an SGLT-2 transporter inhibitor is known to improve glucose control with weight loss. Its role in reducing insulin resistance is under-recognised.

CASE
A young patient with BMI of 47.4 kg/m2 and diabetes has been treated with high dose multiple daily insulin injection totalling 600 iu/day (4.2 iu/kg/day). Despite compliance, lifestyle intervention and add-on therapy of metformin and vildagliptin, insulin requirement only reduced to 275 iu/day(2 iu/kg/day) and remained static. We subsequently started him on 25 mg daily of empaglifozin.

CONCLUSION
In an obese patient with insulin resistance, empaglifozin improved insulin sensitivity leading to significant reduction in insulin requirement

Downloads

Download data is not yet available.

References

*

Downloads

Published

2022-06-08

How to Cite

Ooi, X. Y., See, C. K., & Arifin, N. (2022). SEVERE INSULIN RESISTANCE REQUIRING HIGH DOSE INSULIN IMPROVED WITH ADD-ON EMPAGLIFOZIN THERAPY: A CASE REPORT. Journal of the ASEAN Federation of Endocrine Societies, 34(2), 55. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/2045

Issue

Vol. 34 No. 2 (2019): AFES Book of Abstracts (Supplement)

Section

Abstracts of Case Reports | Prediabetes, Diabetes, Hypoglycemia

License

Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).

To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.

A written agreement shall be emailed to the requester should permission be granted.